FDA Brief

Warning letters Food

FDA warning letter to

Organa International Corp.

High riskIssued Oct 13, 2021Posted Oct 26, 2021Office of Human and Animal Food Operations Division West 4

FDA warned Organa International that it sold colloidal minerals, tea, and silver gel as unapproved drugs using disease claims on its website.

What happened

FDA reviewed www.organa.net and the company’s Facebook page in June 2021 and found products for sale with claims and testimonials that they treat, cure, or prevent diseases such as cancer, HIV, anemia, infections, and eye disease. FDA also found dietary supplement labeling problems, including missing or incorrect “dietary supplement” identity, serving size, servings per container, and Supplement Facts format.

What FDA found

  1. FDA says the products are unapproved new drugs because they are sold for disease treatment or prevention without FDA approval.

    sections 201(p), 301(d), and 505(a) of the FD&C Act [21 U.S.C. 321(p), 331(d), 355(a)]
  2. FDA says the drug products lack adequate directions for safe use by a layperson for the serious diseases named.

    section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  3. FDA says the supplement labels fail to identify the products with the term “dietary supplement.”

    section 403(s)(2)(B) of the FD&C Act; 21 CFR 101.3(g)
  4. FDA says the labels have incorrect or missing serving sizes and fail to give the metric quantity for the serving size.

    section 403(q)(1)(A) of the FD&C Act [21 U.S.C. 343(q)(1)(A)]; 21 CFR 101.9(b), 101.12 Table 2, 101.9(b)(7)
  5. FDA says the labels fail to declare the number of servings per container.

    sections 403(q)(1)(B) and 403(q)(5)(F) of the FD&C Act [21 U.S.C. 343(q)(1)(B), 343(q)(5)(F)]; 21 CFR 101.36(b)(1)(ii)
  6. FDA says the Supplement Facts labels are not boxed or formatted as required and use “Supplemental Facts” instead of “Supplement Facts.”

    section 403(q)(5)(F) of the FD&C Act [21 U.S.C. 343(q)(5)(F)]; 21 CFR 101.36(e)(1), (e)(2), (e)(3)(ii)

What FDA wants

FDA asks Organa to correct the violations, stop the drug claims, fix the supplement labels, and respond to the letter. The excerpt provided does not state a response deadline.

Who should pay attention

  • dietary supplement brands that make disease claims
  • online sellers of colloidal silver and mineral products
  • label reviewers for supplement companies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk